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Objective:Cannabis use is associated with a younger age at
onset of psychosis, an indicator of poor prognosis, but bet-
ter cognitive function, a positive prognostic indicator. We
aimed to clarify the role of age at onset and cognition on
outcomes in cannabis users with first-episode schizophrenia
as well as the effect of cannabis dose and cessation of use.
Methods: Ninety-nine patients without alcohol or sub-
stance abuse other than cannabis were divided into lifetime
users and never-users of cannabis and compared on meas-
ures of premorbid function, cognition, and clinical outcome.
Results: Cannabis users demonstrated better cognition at
psychosis onset, which was explained by higher premorbid
IQ. They also showed better social function and neither
measure changed over the subsequent 15 months. Cannabis
users had an earlier age at onset of psychosis, and there was
a strong linear relationship between age at first cannabis
use and age at onset of both prodromal and psychotic symp-
toms. Cannabis use spontaneously declined over time with
3-quarters of users giving up altogether. Later age at first
cannabis use predicted earlier cessation of use and this in
turn was linked to fewer positive psychotic symptoms
and days in hospital during the first 2 years. Conclusions:
Cannabis use brings forward the onset of psychosis in peo-
ple who otherwise have good prognostic features indicating
that an early age at onset can be due to a toxic action of
cannabis rather than an intrinsically more severe illness.
Many patients abstain over time, but in those who persist,
psychosis is more difficult to treat.
Key words: cognition/prognosis/longitudinal
Introduction
Recent evidence suggests that cannabis use during ado-
lescence increases the risk of developing psychosis.1
The evidence as to whether psychosis outcomes are worse
in schizophrenia patients who use cannabis is more
inconsistent, with the strongest being for poor treat-
ment adherence and increased frequency of relapse and
rehospitalisation.2,3
Evaluating psychosis outcomes in cannabis users is
complex because some of the reported characteristics
of this group may in themselves influence prognosis
over and above the continuing influence of cannabis
use. For example, several studies show that cannabis
users have an earlier age at onset of psychosis than
never-users.4 Earlier age at onset is associated with poor-
er outcomes in schizophrenia and is considered to reflect
the severity of the underlying neuropathological process.5
On the other hand, different studies find that people with
schizophrenia and cannabis use tend to have better cog-
nitive function than nonsubstance users.6 This seems in-
compatible with the age at onset effect as better cognitive
function is thought to reflect greater cognitive reserve and
less illness severity.7 This is supported by findings in
schizophrenia that higher premorbid IQ and IQ at psy-
chosis onset predict better functional outcomes in the
early years of illness.8
Taken together, these 2 observations suggest that can-
nabis can trigger psychosis earlier in individuals who oth-
erwise have good prognostic features and that the age at
onset effect may be due to an action of cannabis rather
than a reflection of an intrinsically more severe illness.
We tested this hypothesis by examining age at onset of
psychosis and cognition in schizophrenia patients with
no substance abuse other than cannabis and tobacco
and compared these with patients who had never used
cannabis. We predicted that cannabis users would dem-
onstrate evidence of higher cognitive reserve and have an
earlier age at onset.We also predicted that if cannabis use
brings forward the onset of psychosis, then there would
be a temporal relationship between age at first use of can-
nabis and age of onset of not only frank psychosis
but also prodromal symptoms. Finally, in order to under-
stand how cannabis use influences clinical outcomes
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other than age of onset, we examined the effect of fre-
quency of use and cessation of use on symptoms, social
function, and time spent in hospital over the 2 years fol-
lowing psychosis onset. If cannabis users have an intrin-
sically less severe form of the illness as hypothesized,
abstinence should result in better outcomes than persis-
tent use.
Methods
Subjects
Inpatients and outpatients with a first-psychotic episode
were recruited as part of theWest London study and were
eligible if aged between 16 and 60 years and had received
<12 weeks of antipsychotic medication. Diagnoses
according toDiagnostic and Statistical Manual of Mental
Disorders, Fourth Edition criteria were ascertained using
the diagnostic module of the Diagnostic Interview for
Psychosis-Diagnostic Module (DIP-DM).9
One hundred and twenty-one patients were eligible
for inclusion in the current study on the basis that
they had received a diagnosis of schizophrenia, schizo-
phreniform, or schizoaffective disorder and had com-
pleted all neuropsychological and clinical assessments
at presentation. We excluded 22 patients who reported
abuse or dependency on alcohol according to the Alco-
hol Use Scale10 or use of other substances on more than
a monthly basis at any point in their life, which left a fi-
nal sample of 99 patients. Tobacco use was not an ex-
clusion criterion because of its high association with
cannabis use.
We obtained Research Ethics Committee approval to
conduct the study. Participants gave written informed
consent and received an honorarium for their time.
This is a different patient cohort to that previously
reported.11
Substance Use Assessment
Information on substance use was obtained using the
semistructured interview within the DIP-DM.
For each drug used, age at first use, amount and max-
imum frequency of use over the lifetime, the previous
12 months and previous 3 months were documented.
The DIP-DM records frequency of use on a 5-point sca-
le as ‘‘not used,’’ ‘‘daily or almost daily,’’ ‘‘1–2 days
a week,’’ ‘‘2–4 times a month,’’ and ‘‘less than monthly.’’
Cannabis users were defined as those reporting having
used the drug at all during their lifetime. For the purpose
of this study, we collapsed cannabis use into 3 categories:
nonuser, high-frequency user (comprised of those
patients who reported ‘‘daily or almost daily use’’),
and low-frequency user (comprised of patients reporting
a pattern of cannabis use fitting 1 of the remaining 3 cat-
egories of use). This cutoff was chosen because daily or
almost daily use suggests habitual use, whereas use at
a frequency of twice a week or less suggests recreational
use.
The Alcohol Use Scale10 was used to elicit details of
alcohol use during the past 6 months, classified as absti-
nent, use without impairment, abuse, dependence, or de-
pendence with institutionalization.
Neuropsychological Assessments
‘‘Premorbid IQ’’ was estimated using the Wechsler Test
of Adult Reading (WTAR).12 ‘‘Current IQ’’ was mea-
sured using a 4 subtest form of the Wechsler Adult Intel-
ligence Scale III validated for use in schizophrenia.13
‘‘Verbal learning’’ was measured using the Rey Audi-
tory Verbal Learning Task14 in which subjects are read
a list of 15 nouns and asked to recall as many as possible.
The total sum of words recalled over 5 trials was used.
Other tests were from the Cambridge Automated Neuro-
psychological Test Battery15 as follows: ‘‘Working mem-
ory manipulation’’: This self-ordered search task
necessitates remembering the location of previously
found ‘‘tokens’’ while searching for new tokens. Total
errors, when a participant returns to the location where
a token has already been found, were measured. ‘‘Work-
ing memory span’’: This test of forward spatial span is
akin to the Corsi block test. The maximum number of
consecutively presented spatial locations that were suc-
cessfully recalled is measured. ‘‘Planning’’: This is anal-
ogous to the Tower of London task. Subjects plan and
execute a sequence of moves of stimuli in a visual array
to match a goal array, with 12 trials in total. The total
number of perfect solutions was measured.
Clinical Assessments
Mental state was assessed with the Scales for the Assess-
ment of Positive and Negative Symptoms.16 Scores for
the 3 symptom-derived syndromes of schizophrenia, neg-
ative, positive, and disorganization were then calculated.
Affective symptoms were assessed with the YoungMania
Rating Scale17 and the Hamilton Rating Scale for De-
pression.18 Social function was assessed using the Social
Function Scale19 which collects information from indi-
viduals on their abilities in various areas of daily living
and occupational and social activity.
The Nottingham Onset Scale20 was used to establish
the timing of onset of prodrome and psychosis. Duration
of prodrome was taken as the time between the 2 and the
duration of untreated psychosis as the time between psy-
chosis onset and treatment initiation. Ages at onset of
prodromal and psychotic symptoms were also calculated
using these data. The Premorbid Social Adjustment Scale
assessed schizoid and schizotypal traits between ages 5–
11 and 12–16 years via patients and career interview.21
Wealsoused theSchedule for theAssessmentof Insight22
to establish patients’ capacity to relabel psychotic experien-
ces, awareness of need for treatment and illness; the
. . eeson et al.
2
 at U
CL Library Services on M
arch 20, 2014
http://schizophreniabulletin.oxfordjournals.org/
D
ow
nloaded from
 
875
Cannabis, Cognition, Age, and Outcome in Psychosis
Compliance Rating Scale23 to assess adherence to medica-
tion; andDIP-DMratings ofmode of illness onset inwhich
patients rate their illnessdevelopmentonascale1–5ranging
from abrupt onset within hours or days to insidious onset
overaperiodgreaterthan6months.Informationonafamily
history of schizophrenia was also elicited. Two years after
initialassessment,acasenotereviewwasperformedtodeter-
mine the number of days spent in hospital.
Analyses
Analyses were performed using SPSS 15. When compar-
ing groups, ANOVA were used or ANCOVA when con-
trolling for another variable. When measures were
compared at different time points, repeated measure
ANOVAs were used. Correlations were tested using
Pearson’s r. To determine predictors of continuous de-
pendent variables, stepwise linear regressions were
used, with goodness of fit evaluated using r2adj, which
is a modification of r2 that adjusts for the number of
explanatory terms in a model. For binary dependent var-
iables, conditional logistic regression was used to deter-
mine predictors of dependent variables. Categorical data
were compared using chi-squared and nonnormally dis-
tributed continuous data using Mann–Whitney.
Results
Cannabis Use, Demographics and Clinical
Characteristics, and Social Function
Cannabis users had a younger age at prodrome and
psychosis onset and were younger at the time of testing.
Cannabis users had better social function at onset than
never-users. There were no differences in symptoms, dura-
tion of untreated psychosis, mode of onset, and social ad-
justment up to the ageof 16years.Antipsychoticmedication
type did not differ but cannabis users were less adherent to
medication at the time of the assessment (table 1).
Cannabis Use and Cognition
Cannabis users showed better cognitive task performance
than never-users on all measures except working memory
manipulation. When premorbid IQ was entered as
Table 1. Demographics, Social, andClinic Functioning in PatientsWithFirst-Episode PsychosisReporting LifetimeCannabis Compared
With Never-Users
Variable Never-Users (NU) (n = 34) Cannabis Users (HF) (n = 65) Comparison
% % X2 P
Sex (% male) 53 71 3.10 .078
Tobacco user (%) 18 72 27.83 <.001
Diagnosis (schizophrenia/
schizophreniform/schizoaffectivea)
79/3/18 92/0/8 2.42 .120
Medication type (second generation/first
generation/botha/naı¨vea)
94/0/6/0 86/9/5/0 3.31 .069
Mean SD Mean SD F df P
Age at testing (y) 28.29 10.87 23.42 6.06 8.26 1,98 .005
Age at prodrome onset (y) 26.35 10.62 21.22 6.04 9.43 1,98 .003
Age at psychosis onset (y) 27.12 10.68 21.97 5.80 9.71 1,98 .002
Years of education (SD) 12.79 2.01 12.46 1.91 0.66 1,98 .420
Mode of onset 3.42 1.30 3.31 1.18 0.20 1,97 .657
Premorbid social adjustment (5–11 y) 2.22 1.02 2.28 0.98 0.08 1,80 .789
Premorbid social adjustment (12–16 y) 2.49 1.04 2.26 0.89 0.96 1,80 .331
Social function 108.24 9.81 113.10 9.13 5.90 1,97 .017
Insight 9.00 4.38 7.70 4.61 1.54 1,83 .218
Compliance 5.53 1.38 4.78 1.66 5.02 1,98 .027
Negative syndrome 0.40 0.28 0.30 0.26 2.86 1,98 .094
Positive syndrome 0.72 0.22 0.72 0.22 0.01 1,98 .990
Disorganization syndrome 0.43 0.33 0.40 0.29 0.26 1,98 .613
Depression 14.32 8.81 13.02 8.87 0.49 1,98 .487
Mania 8.65 10.21 8.70 10.09 0.01 1,97 .979
Mean SD Mean SD U P
Duration of untreated psychosis (wk) 49.29 79.00 38.82 75.19 899 .125
Duration of prodrome (wk) 76.42 142.80 86.34 128.72 931 .284
Note: df, degrees of freedom.
aGroup not included in analysis.
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a covariate, all between group differences in cognition be-
came nonsignificant except planning. Premorbid IQ did
not explain differences in social function (WTAR cova-
riate effect: F1,95 = 0.11, P = .745, Social Function Scale
corrected model: F1,95 = 5.88, P = .017) (table 2).
Age at First Cannabis Use and Age at Illness Onset
Age at psychosis onset did not significantly correlate with
premorbid social adjustment (12–16 years: r = .06, P =
.590) or premorbid IQ (r = .13, P = .250) and was not
different between those with and without a family history
of psychosis (F1,97 = 1.53, P = .880). Males had an earlier
onset (mean = 21.71, SD = 7.52) than females (mean =
27.34, SD = 8.11; F1,97 = 11.77,P = .001). Age at psychosis
onset was not significantly correlated with severity of
symptoms at onset (positive: r = .06, P = .581; negative:
r = .01, P = .908; disorganization: r = .08, P = .452).
Fifty-three patients were able to state with confidence
their age when they first used cannabis. The average
was 15 years, 281 days, and time between first cannabis
use and psychosis onset was 6 years, 33 days. Age at first
cannabis use correlated significantly with age at prodrome
onset (r = .47, P < .001) and psychosis onset (r = .56, P <
.001). Figure 1 shows the correlation between age at first
cannabis use and age at onset of prodrome and psychosis.
Age at first cannabis use was entered into a stepwise
regression model along with sex as potential predictors
of age at psychosis onset; both younger age at first can-
nabis use (b = 0.92, P < .001) and being male (b = 4.40,
P = .002) entered as independent predictors of earlier psy-
chosis onset (model r2 = .43, F2,50 = 18.85, P < .001).
Effects of Frequency of Cannabis Use
Thirty-fivepatientsadmittedtolow-frequency(twiceaweek
or less) and30 tohigh-frequency(dailyoralmostdaily) can-
nabis use during their lifetime.These 2 groupsdidnot differ
on sex (X2 = 1.84, P = .174), age at testing (F1,63 = 0.02, P =
.903), age at onset of prodrome (F1,64 = 0.22, P = .638), or
psychosis (F1,64 = 0.01, P = 0.997), years between first can-
nabisuseandpsychosisonset(F1,51=0.15,P= .699),premor-
bid social adjustment (age 5–11:F1,57 = 0.59, 0.447; age 12–
16: F1,57 = 0.28. P = .600), mode of onset (F1,64 = 0.34, P =
.565), or premorbid IQ (F1,64= 2.00,P = .162). The low-fre-
quency users had significantly higher current IQ (F1,63 =
4.02,P= .049) and showed trend level superiority on verbal
learning (F1,63 = 3.90, P = .053) and workingmemory span
(F1,62=3.03,P= .087).Thegroupsdidnotdifferonworking
memory manipulation (F1,58 = 0.49, P = .486) or planning
(F1,61= 0.25,P= .619).The relationship betweenage at first
cannabisuseandageatonsetofpsychosiswassignificantfor
bothgroups(lowfrequency:r= .38,P= .045;highfrequency:
r = .65, P < .001).
Fifteen-Month Outcome
Seventy-one patients (72%) were reassessed an average of
15 months and 10 days after their initial assessment.
There was no significant difference in the follow-up
rate of the groups (never-users 62%, cannabis users
77%, X2 = 2.53, P = .112).
Symptoms and insight improved over time, with no
group differences in the rate of improvement. Social
Fig. 1. Scatterplot of the relationship between self-reported age at
first cannabis use and age at onset of prodrome and psychosis (n5
53). The dashed line represents the equivalent age on both axes.
Casesbelowthedashed lineare thosewithonsetof cannabisuseafter
onset of prodromal (n 5 3) and psychotic symptoms (n 5 1).
Table 2. Comparison of Cognitive Function at First-Episode in Lifetime Cannabis Users and Never-Users
Cognitive Test Variable
Never-Users Cannabis Users Comparison Premorbid IQ as Covariate
Mean SD Mean SD F df P F df P
WTAR premorbid IQ 88.91 11.73 95.54 12.79 6.33 1,98 .013 –
WAIS-III current IQ 81.15 17.67 89.20 17.51 5.69 1,98 .033 0.29 1,96 .591
Verbal learning 33.12 12.82 38.40 10.81 4.69 1,98 .033 1.10 1,96 .298
Working memory span 4.94 1.37 5.53 1.43 3.91 1,96 .050 1.19 1,94 .278
Working memory manipulationa 40.19 14.14 34.07 18.79 2.15 1,86 .147 —
Planning 5.52 3.39 7.21 2.29 8.66 1,95 .004 5.36 1,93 .023
Note: Comparisons are also shown after controlling for WTAR premorbid IQ. df, degrees of freedom; WAIS, Wechsler Adult
Intelligence Scale; WTAR, Wechsler Test of Adult Reading.
aLower scores are better.
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function, compliance, and cognitive measures remained
stable across time and group. The groups did not differ
on the number of days spent in hospital during the index
admission (never-users mean = 66, SD = 75; cannabis
users mean = 55, SD = 73, F1,65 = 0.26, P = .611) or in
total during the first 2 years of illness (never users
mean = 94, SD = 99, cannabis users mean = 118, SD =
148, F1,65 = 0.39, P = .534) (table 3).
Predictors and Effects of Cannabis Use Cessation
There was attrition in the number reporting cannabis use
during the year leading up to presentation: high fre-
quency = 87%; low frequency = 71%; this had declined
further by the 3 months prior to presentation: high fre-
quency = 60%; low frequency = 51%. To identify factors
contributing to discontinuing cannabis use early in the
course of the illness, we performed a logistic regression
on all lifetime cannabis users with current use at pre-
sentation as the binary dependent variable and potential
predictors—sex, age at psychosis onset, age at first can-
nabis use, frequency of lifetime cannabis use, premorbid
IQ, premorbid social adjustment age 11–16, in a forward
conditional analysis. Age at first cannabis use was the
only significant predictor of persistent use at presentation
(Wald = 6.22, P = .012, OR = 1.43). The mean age at first
cannabis use was 14.53 years (SD = 1.94) for persistent
users and 17.39 years (SD = 4.19) for abstinent users. Pre-
morbid IQ did not differ between persistent and abstinent
cannabis users (F1,64 = 0.04, P = .841).
Of the subgroup assessed at follow-up, none of the
never-user group had taken up cannabis use during this
period. Of the low-frequency users, 23% reported persis-
tent use (20% at low frequency, 3% at high frequency). Of
the high-frequency users, 31% reported persistent use (5%
at high frequency, 26% at low frequency). When only the
past 3 months’ use before follow-up was examined, the
rate of continued use had dropped further to 19% of
low-frequency users and 26% of high-frequency users.
We next examined whether lifetime frequency of use
(low, reference category 0 or high) or abstinence during
the 3 months prior to presentation (persistent, reference
category 0 or abstinent) predicted clinical variables at
presentation in the cannabis users using stepwise regres-
sion. The level of negative symptoms was increased by
high-frequency use (r2adj = .05, b = .25, P = .045) but
not influenced by abstinence. By contrast, positive symp-
toms were fewer in abstinent users (r2adj = .11, b = .35,
P = .004), as were disorganization symptoms (r2adj = .05,
b = .25, P = .043). Affective symptoms, social func-
tion, insight, and compliance were not predicted by
frequency of use or abstinence (all predictors P > .05).
In those cannabis users that were followed-up, we ex-
amined the same binary predictors for relationship with
measures of symptoms and functioning at follow-up.
None of the symptoms or clinical measures at 15-month
follow-up were predicted by lifetime frequency of use or
abstinence prior to presentation (all predictors P > .05).
However, when we examined hospitalizations, the length
of the index admission was shorter in those abstinent at
presentation (r2adj = .14, b = .40, P = .005), as was the
total number of days spend in hospital during the first 2
years (r2adj = .20, b = .46, P = .001). Figure 2 shows the
difference between persistent and abstinent cannabis
users on days in hospital during the first 2 years following
presentation.
Discussion
Some studies have shown that cannabis use is associated
with a younger age at onset of psychosis, which is an in-
dicator of a more severe illness linked to poor prognosis.5
Table 3. Change Over Time in Cannabis Users and Never-Users, With Positive Scores Reflecting Improvement, and RepeatedMeasures
ANOVA Comparing Presentation and Follow-up Measures in These Groups
Measure
Cannabis Users Never-Users Effect of Time Time by Group Interaction
Mean Change SD Change Mean Change SD Change F df P F df P
Negative syndrome 0.15 0.23 0.06 0.27 11.00 1,68 .001 1.65 1,68 .204
Positive syndrome 0.46 0.44 0.33 0.29 62.53 1,68 <.001 1.72 1,68 .194
Disorganization syndrome 0.33 0.29 0.23 0.34 50.07 1,68 <.001 1.78 1,68 .187
Depression 8.59 9.54 7.48 9.45 41.92 1,68 .001 0.20 1,68 .654
Mania 6.75 11.24 5.24 10.99 16.84 1,68 <.001 0.27 1,68 .606
Insight 2.73 6.06 1.06 4.93 5.43 1,57 .023 1.06 1,57 .307
Compliance 0.13 2.77 0.71 1.74 1.64 1,67 .205 0.81 1,67 .372
Social function 2.26 9.30 0.22 9.51 0.70 1,68 .405 1.03 1,68 .314
Current IQ (WAIS-III) 1.73 10.05 0.30 5.96 0.35 1,66 .555 0.71 1,66 .403
Verbal learning 4.07 10.15 1.22 10.85 3.29 1,58 .075 0.95 1,58 .333
Working memory span 0.02 1.32 0.29 0.99 0.59 1,60 .445 0.80 1,60 .374
Working memory manipulation 3.95 18.09 5.63 16.85 3.74 1,56 .058 0.11 1,56 .735
Planning 3.09 0.47 2.87 0.64 1.01 1,62 .317 0.12 1,62 .735
Note: Abbreviations are explained in the first footnote to table 1.
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Others find that cannabis users tend to have better cog-
nitive function than nonusers, which is a good prognostic
indicator.8 These findings suggest that in cannabis users
the earlier age of onset may be related to a toxic effect of
cannabis rather than an intrinsically more severe illness.
The main aim of this study was to examine the relation-
ship between age of onset, cognition, and clinical out-
come in patients with schizophrenia with and without
a history of cannabis use.
To clarify the role of cannabis use in psychosis, we ex-
cluded patients with other substance or alcohol misuse;
69% of the remaining patients reported cannabis use at
some point in their life, and this was daily or almost daily
in over one third.
At psychosis onset, cannabis users exhibited better
cognitive function than never-users and there were no dif-
ferential group changes in cognition over the following 15
months. Cannabis users had higher current IQ and better
verbal learning, working memory span, and planning
ability. The current ability of the cannabis users was
moderated by superior premorbid IQ which, when
covaried, reduced all group differences and rendered
them nonsignificant for current IQ, verbal learning,
and working memory span. This suggests that the group
differences in cognition reflect higher intellectual func-
tioning in the cannabis users prior to psychosis onset.
Some researchers suggest that better cognition in can-
nabis users is due to the drug having a neuroprotective
effect on the developing brain prior to psychosis onset
and base this on evidence from animal models that can-
nabis upregulates neurotrophins and enhances prefrontal
neurotransmitter release.24,25 Others argue that people
who develop schizophrenia in the absence of cannabis
use have different premorbid vulnerabilities, which are
neurodevelopmental and reflected in poor cognition.26,27
If the former hypothesis is true, high-frequency users
should have better cognitive function than low-frequency
users, whereas we found the reverse effect. Thus, our find-
ings support the view that those who develop psychosis in
the context of cannabis use have better cognitive function
because they have fewer neurodevelopmental risk factors
rather than there being an advantageous pharmacologi-
cal action of the drug prior to psychosis onset. This con-
clusion is supported by the observation that the cannabis
users had better social function at onset than never-users,
independently of premorbid IQ and in the context of no
differences in symptom profile or duration of untreated
psychosis.28
Higher cognitive reserve is normally associated with
a later onset of psychosis and is a positive moderator
of the impact of psychosis on clinical outcomes.7,8,29
The cannabis-users in our study had higher cognitive re-
serve than the never-users as evidenced by better premor-
bid IQ and better outcome with respect to social function
over the first 15 months of illness. Yet, we also found that
they had an earlier onset of psychotic symptoms, rep-
licating findings of other studies4 and an earlier onset
of prodromal symptoms. These findings were similar in
low- and high-frequency users suggesting that cannabis
use, even at ‘‘recreational’’ levels, can counteract the nor-
mally protective effect of cognitive reserve on age at psy-
chosis onset and precipitate an earlier onset thanmight be
expected. Male sex was an additional independent risk
factor for an earlier onset of psychosis, in keeping with
other studies.11,30,31 Given the high proportion of males
reporting cannabis use in this study, men may be partic-
ularly at risk of an early onset even with relatively low
levels of cannabis intake.
The link between cannabis use and an early onset of
psychosis is strengthened by our finding of a linear rela-
tionship between the age at first cannabis use and age at
onset of psychotic symptoms. Only one other study that
we know of has reported such a relationship, and this was
in mixed substance users.31 Cannabis use that predates
the onset of psychosis has been hypothesized to reflect
either a response to emergent prodromal symptoms (ie,
‘‘self medication’’) or a factor which predisposes to psy-
chosis development.32 Importantly, in the current study,
age at first cannabis use also predicted age at onset of
prodromal symptoms and in only 3 of the 53 patients
who could confidently date first cannabis use did this
postdate the development of prodromal symptoms.
Our findings therefore support the temporal priority of
cannabis use in the development of psychotic symptoms.
They also complement a study showing that the escala-
tion of frequency of cannabis use up to daily intake short-
ens the time to onset of prodromal and psychotic
symptoms.4 Although we did not find a significant differ-
ence in the time to psychosis onset between low- and
high-frequency users, the effect size for the relationship
between age at first cannabis use, and onset of psychosis
was larger for those with high frequency (r = .65) than low
Fig. 2. Number of days spent in hospital during the first 2 years in
cannabis using patients who were either continuing users at
presentation or abstinent users at presentation and during the
previous 3 months. SE bars are shown for the total number of days.
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frequency (r = .38) use suggesting that the role of cannabis
in time to onset of symptoms may be more prominent in
those patients with daily use.
Earlier first use of cannabis predicted continuing can-
nabis use at the time of psychosis onset, with persistent
users having an average age of first use of 15 years. This
mirrors general population studies, which show that early
cannabis use increases the risk of later dependence.33 In
contrast, population studies report fairly high rates of
persistent cannabis use,34 whereas we found a substantial
attrition of use in our patients. We questioned them
about cannabis use in different phases: lifetime; 12 and
3 months prior to presentation and 12 and 15 months fol-
lowing presentation. The cumulative rates of attrition
were respectively: 29%, 49%, 77%, and 81% for low-
frequency and 13%, 40%, 69%, and 74% for high-
frequency users. In addition, most of the high-frequency
persistent users had reduced the amount they were con-
suming. Similar rates of attrition by the time of presen-
tation have been seen in 2 other first-episode
schizophrenia cohorts,35,36 and longitudinal first-episode
studies found subsequent attrition of cannabis use of
52%,37 42%,35 and 24%.38 Thus, cannabis use in psychosis
patients appears to decline spontaneously during the year
leading up to presentation and continues to decline fol-
lowing treatment initiation. In our study, the mean dura-
tion of untreated symptoms, including the prodrome,
exceeded 1 year in cannabis users. Thus, early abstinence
could have been related to the emergence of psychotic
symptoms by either hindering access or because the
drug had become aversive. In support of the latter, a qual-
itative study found that, comparedwith controls, patients
were more sensitive to the negative effects of cannabis
during the prodromal phase that included depression,
less control over thoughts, and social problems.39 Re-
garding later abstinence and frequency reduction, it is
possible that this was related to antipsychotic medication
causing a reduction of the reinforcing effects of cannabis,
especially as our patients did not receive interventions
specifically aimed at substance abuse.
Early abstinence was clearly beneficial for early out-
come. The cannabis users who had given up by the
time of first contact with services did not differ from
the persistent cannabis users in premorbid IQ or social
function but had fewer positive and disorganization
symptoms, shorter index admissions, and spent fewer
days in hospital during the first 2 years of illness. We
did not observe similar differences in symptoms at the
follow-up assessment, and it is possible that the benefits
of abstinence from cannabis use are most evident in the
early period following giving up, with long-term damage
from cannabis use becoming evident later. Alternatively,
this may have been because a number of those classified
as persistent users at onset had become abstinent in the
follow-up period. Other studies have either reported con-
tinuing psychotic symptoms35,38 or higher rates of
psychotic relapse in persistent cannabis users at follow-
up.2 Our findings are also in accordance with a recent
meta-analysis which concluded that the strongest evi-
dence regarding cannabis and outcome is with regard
to poor treatment adherence and increased frequency
of relapse and rehospitalisation3 as our cannabis users
were less medication adherent than never-users at first
assessment.
In summary, our data suggest that cannabis use may
bring forward the onset of psychosis in people who other-
wise have good prognostic features, as indicated by pre-
morbid cognition and social function. Thus, the earlier
age at onset in cannabis users could be due to the toxic
action of cannabis rather than an intrinsically more se-
vere illness. Public health policies aimed at preventing
cannabis use, if successful, might therefore delay the on-
set of psychosis in vulnerable young people and improve
outcomes further. Although many patients abstain over
time, cannabis use has an additional harmful effect in
those who persist because it makes psychosis more diffi-
cult to treat. Persistent cannabis use after psychosis onset
has been related to a reduction in dysphoria and enhance-
ment of sociability despite patients being aware that it
worsens their psychotic symptoms.40 Thus, focusing on
the treatment of mood disturbance in persistent cannabis
users with prominent affective symptoms may be a strat-
egy to improve already high rates of spontaneous canna-
bis cessation early in the illness.
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